re: one of these It's a strange one this.
The current sp is justified just from the sales growth alone. But when you throw in the potential if the product was marketed properly and the new indictions, with other chemo drugs, other cancers & primary cancers - the sp looks very silly indeed.
Surely now is the time for a bidder to step forward, imho.
genentech inc., page-10
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $2.587K | 14.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 6407725 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1792238 | 19 |
View Market Depth
| Last trade - 13.11pm 31/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |